Potential Drug-Drug Interactions and their Associated Factors at the University Children's Hospital in Syria: A Cross-Sectional Study

Q3 Pharmacology, Toxicology and Pharmaceutics
Linda Hsien, Samir Srour
{"title":"Potential Drug-Drug Interactions and their Associated Factors at the University Children's Hospital in Syria: A Cross-Sectional Study","authors":"Linda Hsien, Samir Srour","doi":"10.35516/jjps.v17i1.1606","DOIUrl":null,"url":null,"abstract":"Objective: Polypharmacy among pediatric inpatients is common and exposes children to the risk of drug-drug interactions (DDIs). This study aimed to characterize potential DDIs (pDDIs) and their associated risk factors among pediatric inpatients.\nMethods: A cross-sectional study was conducted over six months at the University Children's Hospital in Damascus. A total of 575 children taking two drugs or more participated. pDDIs were checked using Lexi-Interact® software. pDDIs within risk category B (No action needed), C (Monitor therapy), D (Modify regimen), and X (Avoid combination) were included. Logistic regression was used to identify factors associated with pDDIs.\nResults: At least one pDDI was detected in 49.7% of children. Overall, 744 pDDIs were identified. The majority of pDDIs were within risk category C (71.6%), followed by D (14%), B (12.8%), and X (1.6%). The most common pDDIs were: aminoglycosides - penicillins (n=56), aminoglycosides - cephalosporins (n=27), and vitamin D analogs - calcium salts (n=23). The number of prescribed drugs and nervous system drugs were significantly associated with the presence of pDDIs.\nConclusion: pDDIs among pediatric inpatients were prevalent. The majority of the pDDIs were within risk category C, which necessitates therapy monitoring and necessary action to avoid adverse consequences.","PeriodicalId":14719,"journal":{"name":"Jordan Journal of Pharmaceutical Sciences","volume":"66 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jordan Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35516/jjps.v17i1.1606","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Polypharmacy among pediatric inpatients is common and exposes children to the risk of drug-drug interactions (DDIs). This study aimed to characterize potential DDIs (pDDIs) and their associated risk factors among pediatric inpatients. Methods: A cross-sectional study was conducted over six months at the University Children's Hospital in Damascus. A total of 575 children taking two drugs or more participated. pDDIs were checked using Lexi-Interact® software. pDDIs within risk category B (No action needed), C (Monitor therapy), D (Modify regimen), and X (Avoid combination) were included. Logistic regression was used to identify factors associated with pDDIs. Results: At least one pDDI was detected in 49.7% of children. Overall, 744 pDDIs were identified. The majority of pDDIs were within risk category C (71.6%), followed by D (14%), B (12.8%), and X (1.6%). The most common pDDIs were: aminoglycosides - penicillins (n=56), aminoglycosides - cephalosporins (n=27), and vitamin D analogs - calcium salts (n=23). The number of prescribed drugs and nervous system drugs were significantly associated with the presence of pDDIs. Conclusion: pDDIs among pediatric inpatients were prevalent. The majority of the pDDIs were within risk category C, which necessitates therapy monitoring and necessary action to avoid adverse consequences.
叙利亚大学儿童医院潜在的药物相互作用及其相关因素:横断面研究
目的:儿科住院病人使用多种药物的情况很普遍,这使儿童面临药物间相互作用(DDI)的风险。本研究旨在描述儿科住院患者中潜在的 DDIs(pDDIs)及其相关风险因素:在大马士革大学儿童医院进行了为期六个月的横断面研究。使用 Lexi-Interact® 软件对 pDDIs 进行了检查。风险类别 B(无需采取行动)、C(监控治疗)、D(修改治疗方案)和 X(避免联合用药)中的 pDDIs 均包括在内。采用逻辑回归法确定与 pDDIs 相关的因素:结果:49.7%的儿童至少发现了一种 pDDI。总共发现了 744 个 pDDI。大多数 pDDI 属于风险类别 C(71.6%),其次是 D(14%)、B(12.8%)和 X(1.6%)。最常见的 pDDIs 是:氨基糖苷类-青霉素类(n=56)、氨基糖苷类-头孢菌素类(n=27)和维生素 D 类似物-钙盐(n=23)。处方药和神经系统药物的数量与 pDDIs 的存在有显著关联。大多数 pDDIs 属于 C 风险类别,需要对治疗进行监测并采取必要行动以避免不良后果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Jordan Journal of Pharmaceutical Sciences
Jordan Journal of Pharmaceutical Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
1.70
自引率
0.00%
发文量
33
期刊介绍: The Jordan Journal of Pharmaceutical Sciences (JJPS) is a scientific, bi-annual, peer-reviewed publication that will focus on current topics of interest to the pharmaceutical community at large. Although the JJPS is intended to be of interest to pharmaceutical scientists, other healthy workers, and manufacturing processors will also find it most interesting and informative. Papers will cover basic pharmaceutical and applied research, scientific commentaries, as well as views, reviews. Topics on products will include manufacturing process, quality control, pharmaceutical engineering, pharmaceutical technology, and philosophies on all aspects of pharmaceutical sciences. The editorial advisory board would like to place an emphasis on new and innovative methods, technologies, and techniques for the pharmaceutical industry. The reader will find a broad range of important topics in this first issue.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信